Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

3.71USD
11:04am EDT
Change (% chg)

$0.06 (+1.64%)
Prev Close
$3.65
Open
$3.67
Day's High
$3.71
Day's Low
$3.65
Volume
29,940
Avg. Vol
461,889
52-wk High
$5.66
52-wk Low
$2.60

Select another date:

Mon, Feb 26 2018

BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY

BRIEF-Achillion Forecasts 2018 Loss Of $0.55-$0.58 Per Share

* ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Achillion Initiates Phase I First-In Study Of ACH-5228

* ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D

BRIEF-Achillion Announces ACH-4471 Granted Orphan Drug Designation For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF C3 GLOMERULOPATHY (C3G) AND THE INITIATION OF A PHASE 1 EXTENDED-RELEASE BIOAVAILABILITY STUDY

BRIEF-Achillion announces pricing of secondary offering of common stock

* Achillion announces pricing of secondary offering of common stock

BRIEF-Achillion announces proposed secondary offering of common stock

* Achillion announces proposed secondary offering of common stock

BRIEF-Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

* Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

BRIEF-Achillion says ACH-4471 granted orphan drug designation by FDA

* Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria

BRIEF-Achillion Q3 loss per share $0.14

* Achillion reports third quarter 2017 financial results and provides update on clinical programs

Select another date: